Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04743713
Other study ID # GO 21/27
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 10, 2021
Est. completion date January 16, 2022

Study information

Verified date February 2021
Source Hacettepe University
Contact Elif Turgut
Phone 0505 6450049
Email elifcamci@hacettepe.edu.tr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose is to perform a scientific study on TURKISH cross-cultural adaptation, validation and the reliability of UWRI


Description:

The primary aim of this study is to perform Turkish cross-cultural adaptation, validation and the reliability of UWRI in runners. The secondary aim of this study is investigating injury rate and types among runners.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date January 16, 2022
Est. primary completion date January 16, 2022
Accepts healthy volunteers No
Gender All
Age group 14 Years to 45 Years
Eligibility Inclusion Criteria: - 14-45 years old female or male - Participating in running as amateur, recreational, competitional or professional runner - Being a short, mid, or long distance runner - Being native Turkish speaker - Agreed to participate in the research Exclusion Criteria: - If there is no surgical history related to running injury in the last 12 months - If have chronic metabolic disease - Paralympic athletes - Pregnant and breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Other:
UWRI-Tr
Questionnaire

Locations

Country Name City State
Turkey Hacettepe University Ankara Çankaya

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validity and reliability pearson's correlation 2 tailed analysis; >0,60 good, 0,31-0,59 medium, <0,30 bad 5-7 days
See also
  Status Clinical Trial Phase
Completed NCT02349373 - Focus of a Running Schedule and Risk of Running Injuries N/A